☒ |
ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
|
☐ |
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
|
Delaware
|
45-2729920
| |
(State or other jurisdiction of incorporation or organization) |
(I.R.S. Employer Identification No.) | |
One Newton Executive Park, Suite 202
Newton, MA |
02462
| |
(Address of principal executive offices)
|
(Zip Code)
|
Title of each class
|
Trading
Symbol
|
Name of each exchange
on which registered
| ||
Common Stock, par value $0.001 per share
|
ALNA
|
The Nasdaq Global Select Market
|
Large accelerated filer | ☐ | Accelerated filer | ☐ | |||
Non-accelerated filer | ☒ | Smaller reporting company | ☒ | |||
Emerging growth company | ☒ |
ITEM 15.
|
EXHIBITS, FINANCIAL STATEMENT SCHEDULES
|
3.
|
List of Exhibits
|
(b)
|
Exhibit Index.
|
Exhibit Number |
Description
| |
31.1* | Certification of Principal Executive Officer pursuant to Exchange Act Rules13a-14(a) and15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 | |
31.2* | Certification of Principal Financial Officer pursuant to Exchange Act Rules13a-14(a) and15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 | |
104 | Cover Page Interactive Data File-the cover page interactive data file does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document. |
* |
Filed herewith.
|
ALLENA PHARMACEUTICALS, INC.
| ||||||
Date: | November 12, 2021 | By: |
/s/ Louis Brenner
| |||
Louis Brenner, M.D.
Chief Executive Officer and Director
(Principal Executive Officer)
|
Attachments
- Original document
- Permalink
Disclaimer
Allena Pharmaceuticals Inc. published this content on 12 November 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 12 November 2021 21:18:41 UTC.